Report Summary
The diagnosed diabetic population in Australia is growing, and patients are continuing to struggle to achieve and maintain target blood glucose levels. These market drivers, combined with a preponderance of safety issues over currently marketed antidiabetics in recent years, implies that the chance for brand new and improved pipeline candidates is lucrative.
Browse all: Banking and Finance Market analysis Reports
Features and benefits
- Provides insight into the key drivers and resistors to antidiabetic medication uptake in Australia
- Analyzes the present diabetes treatment paradigm in Australia
- Assesses key brands within the insulin and non-insulin antidiabetics market in Australia
- Summarizes key pipeline candidates expected to launch in Australia, and their seemingly impacts
Highlights
Despite robust market drivers, the Australian antidiabetics market are often tough to penetrate, with variety of leading world brands facing restrictions in approved indications and difficulties getting reimbursement.
With restricted pipeline development within the insulin category, the main impact on growth can come back from the biosimilar threat, expected to require result in Australia from 2015. Meanwhile, glucagon-like peptide-1 can obtain market share if reimbursement difficulties are often resolved and as longer-acting molecules reach the Australian market.
Oral antidiabetics can still prosper, driven by variety of late-stage pipeline candidates, together with a brand new category of sodium-dependent glucose transporter-2 inhibitors. However, the thiazolidinedione category is anticipated to lose market share to alternative oral antidiabetics with higher long-term safety profiles.
OVERVIEW OF DIABETES IN AUSTRALIA
Australia-specific diabetes epidemiology
sort one diabetes is increasing in incidence, however overall prevalence remains low
sort two diabetes is very prevalent in Australia
Australian diabetes market drivers
The prevalence of diabetes is increasing in Australia
half all Australian diabetes patients don't reach HbA1c target of <7%
The Australian government has committed vital funds to diabetes analysis and management
Launch of novel compounds can stimulate the non-insulin market
Australian diabetes market resistors
Novel antibiotic might struggle to achieve Pharmaceutical edges theme listings
Biosimilars can begin to impact insulin sales
problems with safety and efficacy of thiazolidinediones have jaded some prescribers
Health reforms aim to decrease the diabetes incidence and spending by increasing preventative care and chronic disease management programs
ways to access the Australian antidiabetics market
Novo Nordisk identifies itself as a diabetes-focused company and offers support services
Eli Lilly has to improve its dissemination of physician and patient education
Merck's campaign promoting Januvia to GPs ensured speedy product uptake
Related Reports:
Autistic Disorder Therapeutics - Pipeline Assessment and Market Forecasts to 2018 - http://www.reportsnreports.com/reports/131733-autistic-disorder-therapeutics-pipeline-assessment-and-market-forecasts-to-2018.html
Psoriasis Therapeutics - Pipeline Assessment and Market Forecasts to 2018 - http://www.reportsnreports.com/reports/131735-psoriasis-therapeutics-pipeline-assessment-and-market-forecasts-to-2018.html
Incoming search terms
antidiabetics market,pharmaceutical,diabetes treatment,diabetes medication,diabetic market analysis,antidiabetic report
